'Blow Your Mind' Survival Improvement in Advanced, Mutated NSCLC

(MedPage Today) — BERLIN — Almost half of patients with advanced ALK-positive non-small cell lung cancer (NSCLC) have lived 7 years or longer following initial treatment with the ALK inhibitor alectinib (Alecensa), an updated analysis of a…

Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118017

Author :

Publish date : 2025-10-18 19:20:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

‘Blow Your Mind’ Survival Improvement in Advanced, Mutated NSCLC

AI and Healthcare; New Drug for Lupus

How Many Young Adults Used Cannabis or Alcohol to Help Sleep?

Related Posts

PRP Shows Potential for Hair Growth in Cancer Survivors

Diabetes Tied to Worse Bladder Cancer Survival in Finland

SGLT2 Inhibitors Can Modulate Adiposopathy in CKD

Lottery Wins: Separating Myths From Evidence

First Drug for Deadly Transplant Complication Gets FDA’s Blessing

Nick Reiner’s Schizophrenia Meds; Depression and Heart Risk; State Mental Hospitals

PRP Shows Potential for Hair Growth in Cancer Survivors

Diabetes Tied to Worse Bladder Cancer Survival in Finland

SGLT2 Inhibitors Can Modulate Adiposopathy in CKD

Lottery Wins: Separating Myths From Evidence

First Drug for Deadly Transplant Complication Gets FDA’s Blessing

Nick Reiner’s Schizophrenia Meds; Depression and Heart Risk; State Mental Hospitals

FDA Approves Mitapivat for Thalassemia-Related Anemia

19 States Sue HHS Over Move to Curtail Youth Gender-Affirming Care

Categories

Archives